Skip to content
Screener

Ligand Pharmaceuticals LGND Total Liabilities & Equity

Total Liabilities & Equity at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$19.82B+8.2%
Roivant Sciences logo
Roivant SciencesROIV
$5.31B+5.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$967.46M+32.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$1.7B+27.7%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$504.61M+187%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively2020
Additional paid-in capital379,769400,649
Accumulated other comprehensive income4,4768,455
Retained earnings583,251608,088
Total stockholders’ equity967,5161,017,212
Total liabilities and stockholders’ equity$2,185,875$1,560,637

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's total liabilities & equity?
Ligand Pharmaceuticals (LGND) reported total liabilities & equity of $2.19B in Q2 2026.
How has Ligand Pharmaceuticals's total liabilities & equity changed year-over-year?
Ligand Pharmaceuticals's total liabilities & equity increased by 130.4% year-over-year, from $948.6M to $2.19B.
What is the long-term trend for Ligand Pharmaceuticals's total liabilities & equity?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total liabilities & equity has grown at a 2.8% compound annual growth rate (CAGR), from $1.36B to $1.56B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Ligand Pharmaceuticals's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude